Human Pcid2 protein soluble expression method, anti-human Pcid2 protein monoclonal antibody 2D7-F11, and hybridoma cell line secreting antibody
A monoclonal antibody, soluble technology, applied in the direction of anti-animal/human immunoglobulin, analytical materials, animal/human peptides, etc., can solve the problems of decreased number of B cells, apoptosis, etc.
- Summary
- Abstract
- Description
- Claims
- Application Information
AI Technical Summary
Problems solved by technology
Method used
Image
Examples
Embodiment 1
[0038] Preparation and purification of soluble Pcid2 recombinant protein
[0039] (1) Expression plasmid construction
[0040] Generally speaking, the prokaryotic expression strategy using Escherichia coli is the simplest and easiest protein expression strategy in terms of the difficulty of expressing recombinant proteins. We successfully obtained soluble Pcid2 protein by prokaryotic expression. First, in order to express the Pcid2 protein and its interacting protein Dss1, we amplified the two sequences (NCBI sequence numbers NP_001120675.1, NP_006295.1) from cDNAs using PCR technology, and constructed them into Novagen after restriction enzyme digestion and ligation. The commercialized prokaryotic expression vector pETDuet-1, in which Pcid2 protein has a His tag for purification of recombinant protein, while Dss1 does not have any tag. The pDuet plasmid ensures simultaneous translational expression of both proteins.
[0041] Expression vector construction process:
[0042...
Embodiment 2
[0083] (1) Preparation of hybridoma
[0084] The recombinant human Pcid2 / Dss1 protein obtained in Example 1 was used as an antigen to immunize Balb / c mice (purchased from Beijing Weitong Lihua Experimental Animal Technology Co., Ltd.), intraperitoneally injected, and each mouse was injected with 50 micrograms of recombinant human Pcid2 / Dss1 protein. Two weeks later, the mice were immunized again, with the same injection volume and method. After the mouse serum titer reaches the requirement, that is, the titer reaches above 1:200, the cell fusion is prepared, and the mice are subjected to shock immunization three days before the fusion.
[0085] Mouse myeloma cells Sp2 / 0 (ATCC CRL-1772) were prepared at the same time as the mice were immunized.
[0086] Fusion of sensitized B lymphocytes isolated from the spleen of immunized mice with myeloma cells Sp2 / 0 (ATCC CRL-1772) ("Practical Immunology", edited by Yang Tingbin, Changchun Publishing House, published in December 1994) ,...
Embodiment 3
[0093] Identification of 2D7-F11 mAb
[0094] The 2D7-F11 monoclonal antibody prepared in Example 2 was subjected to western blotting on recombinant human Pcid2 protein and human tumor cell line cell lysate according to conventional methods. like figure 2 As shown, the 2D7-F11 monoclonal antibody has a strong positive reaction with recombinant human Pcid2 protein and cells expressing human natural Pcid2 protein, but has no cross-reaction with other proteins including Dss1.
[0095] The 2D7-F11 monoclonal antibody prepared in Example 2 was subjected to immunofluorescence reaction against tumor cell lines HeLa, MCF-7, HepG2 (purchased from Xiehe Cell Bank) and the like according to conventional methods. The results showed that the 2D7-F11 mAb had a strong positive reaction with cells expressing human native Pcid2, as shown in image 3 displayed.
[0096] The 2D7-F11 monoclonal antibody prepared in Example 2 performs immunoprecipitation reaction with the lysate of MCF-7 cells...
PUM

Abstract
Description
Claims
Application Information

- R&D Engineer
- R&D Manager
- IP Professional
- Industry Leading Data Capabilities
- Powerful AI technology
- Patent DNA Extraction
Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.
© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com